NEW YORK, NY--(Marketwired - March 03, 2014) - Taglich Brothers, Inc
. announces it initiated coverage of CollabRx, Inc
CollabRx, Inc. (NASDAQ: CLRX), headquartered in Raleigh, San Francisco, CA, is a bioinformatics company. A specialized medical database built by the company, continually updated by software systems tap into an array of online medical and scientific resources and collect input from more than 75 experts at academic and medical institutions. That information provides substantial value-add content to results of genetic tests ordered for the diagnosis and evaluation of cancer cases. The information provided by CollabRx provides clinicians with actionable information for treatment strategies that draw on expert opinions and current data on relevant pharmaceuticals and clinical trials.
CollabRx's data content and analytics provide treatment decision support to oncologists, a choice dictated by the high US cancer mortality rate and the demonstrated clinical utility of genomic testing in cancer treatment. Sharp reductions in the cost of genetic testing have placed the service within easier reach of physicians, contributing to an increase in demand.
Unlike genomic laboratories that bundle in-house analytics with their test results, CollabRx is a pure bioinformatics company that draws its data from, and bases its analytics on, independent resources, including 75 uncompensated clinicians from leading academic institutions. Through products delivered via SaaS (software-as-a-service), CollabRx provides reference and hospital laboratories with a high-value service add-on while sparing them the need to make sizable investments in computer equipment and software development.
The complete 16-page report is available at www.taglichbrothers.com.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.
All research issued by Taglich Brothers, Inc. is based on public information.
For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.